Table 1.
Participant characteristics (n = 58)
| Mean (±SD) | |
|---|---|
| Demographics | |
| Age at PSG (years) | 61.4 ± 6.3 |
| Age at CSF sample (years) | 59.3 ± 6.1 |
| Interval from CSF sample to PSG (years) | 2.1 ± 2.1 |
| Female (n;%) | 38; 65.5 |
| APOE ε4-positivegenotype (n, %) | 15; 25.9 |
| Parental history of AD positive (n, %) | 45; 77.6 |
| Geriatric depression scale | 0.6 ± 1.1 |
| Education (years) | 16.5 ± 2.1 |
| Sleep architecture | |
| Time in bed (minutes) Total sleep time (minutes) |
446.5 ± 57.8 347.8 ± 71.3 |
| Sleep onset latency (minutes) | 19.1 ± 23.0 |
| Sleep efficiency (%) | 78.0 ± 13.2 |
| Wake after sleep onset (minutes) | 79.6 ± 51.9 |
| Stage N1 (%) | 9.0 ± 9.6 |
| Stage N2 (%) | 58.6 ± 11.0 |
| Stage N3 (%) | 14.3 ± 11.0 |
| Stage REM (%) | 17.9 ± 6.0 |
| Apnea–hypopnea index (AHI; number/hour) | 7.9 ± 12.5 |
| AHI < 5 (n, %) | 34; 58.6 |
| AHI 5–<15 (n, %) | 15; 25.9 |
| AHI 15—<30 (n, %) | 5; 8.6 |
| AHI 30 + (n ,%) | 4; 6.9 |
| Respiratory disturbance index (number/hour) | 15.6 ± 16.5 |
| Periodic leg movements index (number/hour) | 16.8 ± 19.0 |
| Cerebrospinal fluid biomarkers | |
| GFAP (ng/L) | 8.18 ± 2.7 |
| S100B (ng/mL) | 1.19 ± 0.27 |
| YKL-40 (pg/mL) | 132.4 ± 44.3 |
| sTREM2 (pg/mL) | 7.8 ± 2.2 |
| Aβ 42/40 | 0.069 ± 0.010 |
| Aβ 40 (pg/mL) | 13514 ± 3994 |
| Aβ 42 (pg/mL) | 933 ± 321 |
| t-tau (pg/mL) | 179.2 ± 69.3 |
| p-tau (pg/mL) | 15.0 ± 4.3 |
| α-synuclein (pg/mL) | 135.6 ± 62.3 |
| neurogranin (pg/mL) | 677.0 ± 245.5 |
| NfL (pg/mL) | 92.1 ± 119.3 |
AD denotes Alzheimer’s disease, APOE denotes apolipoprotein E, Aβ denotes β-amyloid, CSF denotes cerebrospinal fluid, GFAP denotes Glial fibrillary acidic protein, NfL denotes neurofilament light chain protein, PSG denotes polysomnography, p-tau denotes phosphorylated tau, S100B denotes calcium binding protein B, sTREM2 denotes soluble triggering receptor expressed on myeloid cell 2, t-tau denotes total tau, YKL-40 denotes chitinase-3-like protein.